High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal β-amyloid in Parkinson disease

Neuroscience Letters

Volumn 487, Issue 2, 2011, Pages 169-173

  Compta, Yaroslau ^a   Ezquerra, Mario ^a   Muñoz, Esteban ^a   Tolosa, Eduardo ^a   Valldeoriola, Francesc ^a   Rios, Jose ^b   Cámara, Ana ^a   Fernández, Manel ^a   Buongiorno, Maria Teresa ^a   Marti, Maria Jose ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Alzheimer disease; Amyloid ; Cerebrospinal fluid; Dementia; Parkinson disease; Tau

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN;

AGED; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MALE; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC MARKERS; GENETIC VARIATION; HUMANS; MALE; PARKINSON DISEASE; PEPTIDE FRAGMENTS; POLYMORPHISM, GENETIC; TAU PROTEINS;

EID: 78650220457     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.10.015     Document Type: Article

References (42)

1. Aarsland D., Andersen K., Larsen J.P., Lolk A., Kragh-Sørensen P P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol. 2003, 60:387-392.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychological Association, Washington. fourth ed.
3. Apaydin H., Ahlskog J.E., Parisi J.E., Boeve B.F., Dickson D.W. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch. Neurol. 2002, 59:102-112.
4. Baker M., Litvan I., Houlden H., Adamson J., Dickson D., Perez-Tur J., Hardy J., Lynch T., Bigio E., Hutton M. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum. Mol. Genet. 1999, 8:711-715.
5. Blennow K., Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003, 2:605-613.
6. Christensen D.D. Changing the course of Alzheimer's disease: anti-amyloid disease-modifying treatments on the horizon. Prim. Care Companion J. Clin. Psychiatry 2007, 9:32-41.
7. Compta Y., Martí M.J., Ibarretxe-Bilbao N., Junqué C., Valldeoriola F., Muñoz E., Ezquerra M., Ríos J., Tolosa E. Cerebrospinal tau, phospho-tau and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov Disord. 2009, 24:2203-2210.
8. Cruchaga C., Vidal-Taboada J.M., Ezquerra M., Lorenzo E., Martinez-Lage P., Blazquez M., Tolosa E. The iberian atypical parkinsonism study group researchers 5'-upstream variants of CRHR1 and MAPT genes associated with age at onset in progressive supranuclear palsy and cortical basal degeneration. Neurobiol. Dis. 2009, 33:164-170.
9. Emre M., Aarsland D., Brown R., Burn D.J., Duyckaerts C., Mizuno Y., Broe G.A., Cummings J., Dickson D.W., Gauthier S., Goldman J., Goetz C., Korczyn A., Lees A., Levy R., Litvan I., McKeith I., Olanow W., Poewe W., Quinn N., Sampaio C., Tolosa E., Dubois B. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov. Disord. 2007, 22:1689-1707.
10. Ezquerra M., Campdelacreu J., Gaig C., Compta Y., Muñoz E., Martí M.J., Valldeoriola F., Tolosa E. Lack of association of APOE and tau polymorphisms with dementia in Parkinson's disease. Neurosci. Lett. 2008, 448:20-23.
11. Ezquerra M., Pastor P., Gaig C., Vidal-Taboada J.M., Cruchaga C., Muñoz E., Martí M.J., Valldeoriola F., Aguilar M., Calopa M., Hernandez-Vara J., Tolosa E. Different MAPT haplotypes are associated with Parkinson's disease and progressive supranuclear palsy. Neurobiol. Aging 2010, (PMID: 19879020).
12. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., LaRossa G.N., Spinner M.L., Klunk W.E., Mathis C.A., DeKosky S.T., Morris J.C., Holtzman D.M. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 2006, 59:512-519.
13. Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., Myers R.H., Pericak-Vance M.A., Risch N., van Duijn C.M. Effect of age sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer's disease: a meta analysis. JAMA 1998, 278:1349-1356.
14. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state" A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12:189-198.
15. Goris A., Williams-Gray C.H., Clark G.R., Foltynie T., Lewis S.J., Brown J., Ban M., Spillantini M.G., Compston A., Burn D.J., Chinnery P.F., Barker R.A., Sawcer S.J. Tau and alpha-synuclein in susceptibility to, and dementia in Parkinson's disease. Ann. Neurol. 2007, 62:145-153.
16. Healy D., Abou-Sleiman P.M., Lees A.J., Casas J.P., Quinn N., Bhatia K., Hingorani A.D., Word N.W. Tau gene and Parkinson's disease: a case-control study and meta-analysis. J. Neurol. Neurosurg. Psychiatry 2004, 75:962-965.
17. Hely M.A., Reid W.G., Adena M.A., Halliday G.M., Morris J.G. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov. Disord. 2008, 23:837-844.
18. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 1967, 17:427-442.
19. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 1992, 55:181-184.
20. Kalaitzakis M.E., Graeber M.B., Gentleman S.M., Pearce R.K. Striatal beta-amyloid deposition in Parkinson disease with dementia. J. Neuropathol. Exp. Neurol. 2008, 67:155-161.
21. Kauwe J.S., Cruchaga C., Mayo K., Fenoglio C., Bertelsen S., Nowotny P., Galimberti D., Scarpini E., Morris J.C., Fagan A.M., Holtzman D.M., Goate A.M. Variation in TAU is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:8050-8054.
22. Kurz M.W., Dekomien G., Nilsen O.B., Larsen J.P., Aarsland D., Alves G. APOE alleles in Parkinson disease and their relationship to cognitive decline: a population-based, longitudinal study. J Geriatr. Psychiatry Neurol. 2009, 22:166-170.
23. Lashley T., Holton J.L., Gray E., Kirkham K., O'Sullivan S.S., Hilbig A., Wood N.W., Lees A.J., Revesz T. Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients. Acta Neuropathol. 2008, 115:417-425.
24. Laws S.M., Friedrich P., Diehl-Schmid J., Müller J., Eisele T., Bäuml J., Förstl H., Kurz A., Riemenschneider M. Fine mapping of the TAU locus using quantitative trait analysis identifies possible causal variants in Alzheimer's disease. Mol. Psychiatry 2007, 12:510-517.
25. Maetzler W., Liepelt I., Reimold M., Reischl G., Solbach C., Becker C., Schulte C., Leyhe T., Keller S., Melms A., Gasser T., Berg D. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol. Dis. 2009, 34:107-112.
26. Masliah E., Rockenstein E., Veinbergs I., Sagara Y., Mallory M., Hashimoto M., Mucke L. Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:12245-12250.
27. Mollenhauer B., Trenkwalder C., von Ahsen N., Bibl M., Steinacker P., Brechlin P., Schindehuette J., Poser S., Wiltfang J., Otto M. Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement. Geriatr. Cogn. Disord. 2006, 22:200-208.
28. Myers A.J., Kaleem M., Marlowe L., Pittman A.M., Lees A.J., Fung H.C., Duckworth J., Leung D., Gibson A., Morris C.M., de Silva R., Hardy J. The H1c haplotype at the TAU locus is associated with Alzheimer's disease. Hum. Mol. Genet. 2005, 14:2399-2404.
29. Parnetti L., Tiraboschi P., Lanari A., Peducci M., Padiglioni C., D'Amore C., Pierguidi L., Tambasco N., Rossi A., Calabresi P. Cerebrospinal fluid markers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol. Psychol. 2008, 64:850-855.
30. Parsian A., Racette B., Goldsmith L.J., Perlmutter J.S. Parkinson's disease and apolipoprotein E: possible association with dementia but not age at onset. Genomics 2002, 79:458-461.
31. Pastor P., Ezquerra M., Muñoz E., Martí M.J., Blesa R., Tolosa E., Oliva R. Significant association between the tau gene A0/A0 genotype and Parkinson's disease. Ann. Neurol. 2000, 47:242-245.
32. Perneger T.V. What's wrong with Bonferroni adjustments. Br. Med. J. 1998, 316:1236-1238.
33. Pittman A.M., Myers A.J., Abou-Sleiman P., Fung H.C., Kaleem M., Marlowe L., Duckworth J., Leung D., Williams D., Kilford L., Thomas N., Morris C.M., Dickson D., Wood N.W., Hardy J., Lees A.J., de Silva R. Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J. Med. Genet. 2005, 42(11):837-846.
34. Prince J.A., Zetterberg H., Andreasen N., Marcusson J., Blennow K. APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology 2004, 62:2116-2118.
35. Sabbagh M.N., Adler C.H., Lahti T.J., Connor D.J., Vedders L., Peterson L.K., Caviness J.N., Shill H.A., Sue L.I., Ziabreva I., Perry E., Ballard C.G., Aarsland D., Walker D.G., Beach T.G. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis. Assoc. Disord. 2009, 23:295-297.
36. Saunders A.M., Strittmatter W.J., Schmechel D., George-Hyslop P.H., Pericak-Vance M.A., Joo S.H., Rosi B.L., Gusella J.F., Crapper-MacLachlan D.R., Alberts M.J. Association of apolipoprotein E allele 4 with late-onset familial and sporadic Alzheimer's Disease. Neurology 1993, 43:1467-1472.
37. Schneider A., Mandelkow E. Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics 2008, 5:443-457.
38. Simón-Sánchez J., Schulte C., Bras J.M., Sharma M., Gibbs J.R., Berg D., Paisan-Ruiz C., Lichtner P., Scholz S.W., Hernandez D.G., Krüger R., Federoff M., Klein C., Goate A., Perlmutter J., Bonin M., Nalls M.A., Illig T., Gieger C., Houlden H., Steffens M., Okun M.S., Racette B.A., Cookson M.R., Foote K.D., Fernandez H.H., Traynor B.J., Schreiber S., Arepalli S., Zonozi R., Gwinn K., van der Brug M., Lopez G., Chanock S.J., Schatzkin A., Park Y., Hollenbeck A., Gao J., Huang X., Wood N.W., Lorenz D., Deuschl G., Chen H., Riess O., Hardy J.A., Singleton A.B., Passer T. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 2009, 41:1308-1312.
39. Skipper L., Wilkes K., Toft M., Baker M., Lincoln S., Hulihan M., Ross O.A., Hutton M., Aasly J., Farrer M. Linkage disequilibrium and association of MAPT H1 in Parkinson disease. Am. J. Hum. Genet. 2004, 75:669-677.
40. Williams D.R., De Silva R., Paviour D.C., Pittman A., Watt H.C., Kilford L., Holton J.L., Revesz T., Lees A.J. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005, 128:1247-1258.
41. Yasojima K., McGeer E.G., McGeer P.L. Tangled areas of Alzheimer brain have upregulated levels of exon 10 containing tau mRNA. Brain Res. 1999, 831:301-305.
42. Zhang J., Song Y., Chen H., Fan D. The tau gene haplotype H1 confers a susceptibility to Parkinson's disease. Eur. Neurol. 2005, 53:15-21.